32P - Heterogeneity Analysis of DW MRI as a Biomarker for Prediction of Overall Survival and 6month PFS in GBM Patients
Manijeh Beigi, Tehran, Iran

33P - Somatic mutations of PIK3CA and AKT1 in Japanese breast cancer.
Tatsunori Shimoi, Tokyo, Japan

34P - The expression and functional role of Cripto-1 in human colorectal cancer
Sato Jun, Sendai, Japan

35P - Clinical Significance of Expression of Cripto-1 in Patients of Squamous Cell Carcinoma of Oropharynx
Mallupattu Kumar, Chandigarh, India

36P - Clinical impact and carcinogenic mechanism of USP3 overexpression in gastric cancer
Kai-Yuan Lin, Tainan, Taiwan

37P - Expression pattern of cyclooxygenase-2 in carcinoma of cervix
Shahin Hameed, Cochin, India

38P - Mena INV: a prospective bio-marker of glioma under hypoxia
Mohita Bhagat, Delhi, India

39P - Impact of GSTP1 and ABCC4 Genes Polymorphism on Outbreak of Cyclophosphamide-based Chemotherapy-induced Grade 3/4 Febrile Neutropenia in Iranian Breast Cancer Patients
Maryam Mobaraki, Tehran, Iran

40P - Effect of ABCB1 and SLC22A16 Genes Polymorphism in Outbreak of Doxorubicin-based Chemotherapy-induced Grade 3/4 Febrile Neutropenia in Iranian Breast Cancer Patients
Abolfazl Faraji, Tehran, Iran

41P - Impact prognosis of cellular CD 69 expression with CD 38 in Egyptian Chronic lymphocytic leukemia
Mohamed Elbaiomy, Dakahlia, Egypt

42P - Promoter hypermethylation of BRCA1, DAPK1 and RASSF1A is associated with increase mortality among breast cancer patients.
Prasant Yadav, New Delhi, India

43P - Integrated analysis of genome-wide DNA methylation and gene expression profiles identifies potential novel biomarkers of rectal cancer
Guodong Li, Harbin, China

44P - Pharmacogenetic methods of personalization in medical treatment of colon cancer
Jamshid Ibragimov, Tashkent, Uzbekistan

45P - MiR-183 is frequenty methylated and related to poor survival in human hepatocellular carcinoma
Sumadi Lukman Anwar, Yogyakarta, Indonesia

46P - Identification of novel biomarkers distinguishing pancreatic head cancer from distal cholangiocarcinoma discovered by proteomics analysis
Tsutomu Takenami, Sendai, Japan

47P - Loss-of-function PTPRT and PTPRD mutations predict bevacizumab resistance in metastatic colorectal cancer patients
Kien Thiam Tan, Taipei, Taiwan

48P - Inhibition of LAP2α can sup
in breast cancer
Xiaofen Li, Hangzhou, China

49P - The role of circulating cell-fr
fluorescent assay to predict relapse
receiving neoadjuvant chemotherap
Kwonoh Park, Seoul, Republic of Ko

50P - Droplet digital PCR measured
in plasma cell free DNA in patients w
Hong-Fei Gao, Guangzhou, China

51P - Clinical Feasibility of EGFR M
in Plasma Cell-free DNA of Lung Ade
Yang Yang, Nanjing, China

52P - Expression of CT antigens in P
Potential minimally-invasive Biomarke
Shivam Singh, Delhi, India

53P - Update results of a novel assay
CpGs from sputum to screen patients w
Takeshi Nagasaka, Okayama, Japan

54P - Circulating prostate-specific anti
nationally representative sample of men
Wahyu Wulaningsih, London, UK

55P - CTC Count & Gene Expression P
Herdee Gloriane Luna, Quezon City, Philip

56P - Single Circulating Tumor Cells Ri
Enrichment and Active Single Cell Selec
System
Yi Fang Lee, Singapore

57P - Inter-observer variability in progra
immunohistochemistry scoring in non sm
Alesha Thai, Heidelberg, Australia

58P - PDL1 expression associated with w
in malignant pleural mesothelioma.
Bella Nguyen, Canberra, Australia

59P - Characterization of PD-L1 expressio
cell lung cancer patients with PTEN IHC as
screening
Xu-Chao Zhang, Guangzhou, China

60P - Expression of PD-L1 is associated w
in breast cancer: a meta-analysis
Minghui Zhang, Harbin, China

61P - Tumor-infiltrating lymphocytes/macro
outcome in breast cancer.
Yong-Seok Kim, Uijeongbu City, Republic of

421P - Diagnosis of right upper lobar lymph
by modified TLG
Hitoshi Dejima, Nagoya, Japan